Human isoprenoid synthase enzymes as therapeutic targets

Frontiers in Chemistry

Volumn 2, Issue JUL, 2014, Pages

  Park, Jaeok ^a   Matralis, Alexios N ^a   Berghuis, Albert M ^a   Tsantrizos, Youla S ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Farnesyl pyrophosphate; Geranylgeranyl pyrophosphate; Isoprenoids; Mevalonate pathway; Squalene

Indexed keywords

EID: 84987660393     PISSN: None     EISSN: 22962646     Source Type: Journal    
DOI: 10.3389/fchem.2014.00050     Document Type: Review

References (181)

1. Amin, D., Rutledge, R. Z., Needle, S. N., Galczenski, H. F., Neuenschwander, K., Scotese, A. C., et al. (1997). RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther. 281, 746-752.
2. Amstutz, R., Bold, G., Cotesta, S., Jahnke, W., Marzinzik, A., Mueller-Hartwieg, C., et al. (2009). Quinolines as Inhibitors of Farnesyl Pyrophosphate Synthase. WO 2009/106586 A1
3. Bagi, C. M. (2005). Targeting of therapeutic agents to bone to treat metastatic cancer. Adv. Drug Deliv. Rev. 57, 995-1010. doi: 10.1016/j.addr.2004.12.014
4. Barney, R. J., Wasko, B. M., Dudakovic, A., Hohl, R. J., and Wiemer, D. F. (2010). Synthesis and biological evaluation of a series of aromatic bisphosphonates. Bioorg. Med. Chem. 18, 7212-7220. doi: 10.1016/j.bmc.2010.08.036
5. Baxter, A., Fitzgerald, B. J., Hutson, J. L., McCarthy, A. D., Motteram, J. M., Ross, B. C., et al. (1992). Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J. Biol. Chem. 267, 11705-11708.
6. Benzaïd, I., Mönkkönen, H., Bonnelye, E., Mönkkönen, J., and Clézardin, P. (2012). In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors Trigger Vγ9Vδ 2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin. Cancer Res. 18, 6249-6259. doi: 10.1158/1078-0432.CCR-12-0918
7. Bergstrom, J. D., Kurtz, M. M., Rew, D. J., Amend, A. M., Karkas, J. D., Bostedor, R. G., et al. (1993). Zaragosic acids:a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. U.S.A. 90, 80-84. doi: 10.1073/pnas.90.1.80
8. Biller, S. A., Abt, J. W., Pudzianowski, A. T., Rich, L. C., Slusarchyk, D. A., Ciosek, C. P., et al. (1993). Aromatic isosters as conformational probes for an isoprenyl subunit: application to inhibitors of squalene synthase. Bioorg. Med. Chem. Lett. 3, 595-600. doi: 10.1016/S0960-894X(01)81236-1
9. Biller, S. A., Forster, C., Gordon, E. M., Harrity, T., Rich, L. C., Marretta, J., et al. (1991). Isoprenyl phosphinylformates: new inhibitors of squalene synthetase. J. Med. Chem. 34, 1912-1914. doi: 10.1021/jm00110a024
10. Brown, G. R., Butlin, R. J., Chapman, S., Eakin, M. A., Foubister, A. J., Freeman, S., et al. (1995). Phenoxypropylamines: a new series of squalene synthase inhibitors. J. Med. Chem. 38, 4157-4160. doi: 10.1021/jm00021a003
11. Brown, G. R., Clarke, D. S., Foubister, A. J., Freeman, S., Harrison, P. J., Johnson, M. C., et al. (1996). Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J. Med. Chem. 39, 2971-2979. doi: 10.1021/jm950907l
12. Brown, G. R., Foubister, A. J., Freeman, S., McTaggart, F., Mirrlees, D. J., Reid, A. C., et al. (1997). Novel optimised quinuclidine squalene synthase inhibitors. Bioorg. Med. Chem. Lett. 7, 597-600. doi: 10.1016/S0960-894X(97)00053-X
13. Cao, R., Chen, C. K., Guo, R. T., Wang, A. H., and Oldfield, E. (2008). Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases. Proteins 73, 431-439. doi: 10.1002/prot.22066
14. Caraglia, M., Luongo, L., Salzano, G., Zappavigna, S., Marra, M., Guida, F., et al. (2013). Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain. Mol. Pharm. 10, 1111-1118. doi: 10.1021/mp3006215
15. Chan, C., Andreotti, D., Cox, B., Dymock, B. W., Hutson, J. L., Keeling, S. E., et al. (1996). The squalestatins: decarboxyand 4-deoxy analogues as potent squalene synthase inhibitors. J. Med. Chem. 39, 207-216. doi: 10.1021/jm9504969
16. Chang, S. Y., Hudon-Miller, S. E., Yang, S. H., Jung, H.-J., Lee, E. F., Subramanian, T., et al. (2012). Inhibitors of protein geranylgeranyltransferase-I lead to prelamin A accumulation in cells by inhibiting ZMPSTE24. J. Lipid Res. 53, 1176-1182. doi: 10.1194/jlr.M026161
17. Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., et al. (2011). Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472. doi: 10.1038/nature09837
18. Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., et al. (2007). Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 25, 71-75. doi: 10.1038/nbt1273
19. Chrysselis, M. C., Rekka, E. A., and Kourounakis, A. P. (2000). Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. J. Med. Chem. 43, 609-612. doi: 10.1021/jm991039l
20. Chrysselis, M. C., Rekka, E. A., Siskou, I. C., and Kourounakis, P. N. (2002). Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents. J. Med. Chem. 45, 5406-5409. doi: 10.1021/jm011062i
21. Cimini, E., Piacentini, P., Sacchi, A., Gioia, C., Leone, S., Lauro, G. M., et al. (2011). Zoledronic acid enhances Vd 2 T-lymphocyte antitumor response to human glioma cell lines. Int. J. Immunopathol. Pharmacol. 24, 139-148.
22. Ciosek, C. P. Jr., Magnin, D. R., Harrity, T. W., Logan, J. V., Dickson, J. K. Jr., Gordon, E. M., et al. (1993). Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem. 268, 24832-24837.
23. Coleman, R. E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12, 6243s-6249s. doi: 10.1158/1078-0432.CCR-06-0931
24. Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., et al. (2011). Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 365, 1396-1405. doi: 10.1056/NEJMoa1105195
25. Cornforth, J. W., Cornforth, R. H., Popjak, G., and Yengoyan, L. (1966). Studies on the biosynthesis of cholesterol. XX. Steric course of decarboxylation of 5-pyrophosphomevalonate and of the carbon to carbon bond formation in the biosynthesis of farnesyl pyrophosphate. J. Biol. Chem. 241, 3970-3987.
26. Cotesta, S., Glickman, J. F., Jahnke, W., Marzinzik, A., Ofner, S., Rondeau, J.-M., et al. (2010). Salicylic Acid Derivatives Being Farnesyl Pyrophosphate Synthase Activity Inhibitors. WO 2010/043584 A1
27. Crews, C. M. (2010). Targeting the undruggable proteome: the small molecules of my dreams. Chem. Biol. 17, 551-555. doi: 10.1016/j.chembiol.2010.05.011
28. Dedes, P. G., Gialeli, C., Tsonis, A. I., Kanakis, I., Theocharis, A. D., Kletsas, D., et al. (2012). Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochem. Biophys. Acta 1820, 1926-1939. doi: 10.1016/j.bbagen.2012.07.013
29. De Schutter, J. W., Park, J., Leung, C. Y., Gormley, P., Lin, Y.-S., Hu, Z., et al. (2014). Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase-implications to drug discovery for neurodegenerative diseases. J. Med. Chem. 57, 5764-5776. doi: 10.1021/jm500629e
30. De Schutter, J. W., Shaw, J., Lin, Y.-S., and Tsantrizos, Y. S. (2012). Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active Site "Capping" phenyls. Bioorg. Med. Chem. 20, 5583-5591. doi: 10.1016/j.bmc.2012.07.019
31. Dimopoulos, M. A., Kastritis, E., Bamia, C., Melakopoulos, I., Gika, D., Roussou, M., et al. (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive mjeasures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 20, 117-120. doi: 10.1093/annonc/mdn554
32. Do, R., Kiss, R. S., Gaudet, D., and Engert, J. C. (2009). Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin. Genet. 75, 19-29. doi: 10.1111/j.1399-0004.2008.01099.x
33. Dudakovic, A., Tong, H., and Hohl, R. J. (2011). Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration. Invest. New Drugs 29, 912-920. doi: 10.1007/s10637-010-9446-y
34. Dunford, J. E. (2010). Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Curr. Pharm. Des. 16, 2961-2969. doi: 10.2174/138161210793563617
35. Dunford, J. E., Kwaasi, A. A., Rogers, M. J., Barnett, B. L., Ebetino, F. H., Russell, R. G. G., et al. (2008). Structure-activity relationship among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J. Med. Chem. 51, 2187-2195. doi: 10.1021/jm7015733
36. Dunford, J. E., Thompson, K., Coxon, F. P., Luckma, S. P., Hahn, F. M., Poulter, C. D., et al. (2001). Structure-activity relationship for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296, 235-242.
37. Eastell, R., Walsh, J. S., Watts, N. B., and Siris, E. (2011). Bisphosphonates for postmenopausal osteoporosis. Bone 49, 82-88. doi: 10.1016/j.bone.2011.02.011
38. Ebetino, F. H., Hogan, A.-M., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., et al. (2011). The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49, 20-33. doi: 10.1016/j.bone.2011.03.774
39. Ebetino, F. H., Mazur, A., Lundy, M. W., and Russell, R. G. G. (2010a). 4-Azaindole Bisphosphonates. WO 2010/033980 A2
40. Ebetino, F. H., Mazur, A., Lundy, M. W., and Russell, R. G. G. (2010b). 5-Azaindole Bisphosphonates. WO 2010/033981 A2
41. Ebetino, F. H., Mazur, A., Lundy, M. W., and Russell, R. G. G. (2010c). Imidazo[1, 2-a]pyridinyl Bisphosphonates. WO 2010/033978 A2
42. Eckert, G. P., Hooff, G. P., Strandjord, D. M., Igbavboa, U., Volmer, D. A., Müller, W. E., et al. (2009). Regulation of the brain isoprenoids farnesyl-and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol. Dis. 35, 251-257. doi: 10.1016/j.nbd.2009.05.005
43. Endo, A. (1992). The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569-1582.
44. Ezra, A., Hoffma, A., Breuer, E., Alferiev, I. S., Mönkkönen, J., El Hanany-Rozen, N., et al. (2000). Peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem. 43, 3641-3652. doi: 10.1021/jm980645y
45. Fournier, P. G., Stresing, V., Ebetino, F. H., and Clézardin, P. (2010). How do bisphosphonates inhibit bone metastasis in vivo. NeoPlasia 12, 571-578.
46. Franzoni, F., Quinones-Galvan, A., Regoli, F., Ferrannini, E., and Galetta, F. (2003). A comparative study of the in vitro antioxidant activity of statins. Int. J. Cardiol. 90, 317-321. doi: 10.1016/S0167-5273(02)00577-6
47. 2O)]n. Acta Cryst. C66, m166-m170. doi: 10.1107/S0108270110017634
48. Frost, M. L., Siddique, M., Blake, G. M., Moore, A. E., Marsden, P. K., Schleyer, P. J., et al. (2012). Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. Osteoporos Int. 23, 2107-2116. doi: 10.1007/s00198-011-1805-9
49. Fung, A. K., Baker, W. R., Fakhoury, S., Stein, H. H., Cohen, J., Donner, B. G., et al. (1997). [(1-alpha, 2-beta, 3-beta, 4-alpha)-1, 2-bis[N-propyl-N-(4-phenoxybenzyl)amino]carbonyl]cyclobutane-3, 4-dicarboxylic acid (A-87049): a novel potent squalene synthase inhibitor. J. Med. Chem. 40, 2123-2125. doi: 10.1021/jm970058x
50. Gabelli, S. B., McLellan, J. S., Montalvetti, A., Oldfield, E., Docampo, R., and Amzel, L. M. (2006). Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins 62, 80-88. doi: 10.1002/prot.20754
51. Giger, E. V., Castagner, B., and Leroux, J.-C. (2013). Biomedical applications of bisphosphonates. J. Control. Release 167, 175-188. doi: 10.1016/j.jconrel.2013.01.032
52. Gilad, R., and Lampl, Y. (1999). Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin. Neuropharmacol. 22, 295-297.
53. Glickman, J. F., and Schmid, A. (2007). Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay. Assay Drug Dev. Technol. 5, 205-214. doi: 10.1089/adt.2007.057
54. Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., et al. (2009). endocrine therapy plus zoledronic acid in premenopaisal breast cancer. New Engl. J. Med. 360, 679-691. doi: 10.1056/NEJMoa0806285
55. Goldstein, J. L., and Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature 343, 425-430. doi: 10.1038/343425a0
56. Grey, A., Bolland, M. J., Wattie, D., Horne, A., Gamble, G., and Reid, I. R. (2009). The antiresorptive effects of a single dose of zoledronate persists for two years: arandomized placebo-control trial in osteopenic postmenopausal women. J. Clin. Endocrinol. Metab. 94, 538-544. doi: 10.1210/jc.2008-2241
57. Guo, R. T., Cao, R., Liang, P. H., Ko, T. P., Chang, T. H., Hudock, M. P., et al. (2007). Bisphosphonates target multiple sites in both cis-and trans-prenyltransferases. Proc. Natl. Acad. Sci. U.S.A. 104, 10022-10027. doi: 10.1073/pnas.0702254104
58. Hoff, A. O., Toth, B. B., Altuntag, K., Johnson, M. M., Warneke, C. L., Hu, M., et al. (2008). Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res. 23, 826-836. doi: 10.1359/jbmr.080205
59. Hoffman, A., Ott, A., Breteler, M. M. B., Bots, M. L., Slooter, A. J. C., van Harskamp, F., et al. (1997). Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349, 151-154.
60. Holloway, P. W., and Popjak, G. (1967). The purification of 3, 3-dimethylallyl-and geranyl-transferase and of isopentenyl pyrophosphate isomerase from pig liver. Biochem. J. 104, 57-70.
61. Hooff, G. P., Wood, W. G., Kim, J.-H., Igbavboa, U., Ong, W.-Y., Müller, W. E., et al. (2012). brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice. Mol. Neurobiol. 46, 179-185. doi: 10.1007/s12035-012-8285-6
62. Hooff, G. P., Wood, W. G., Müller, W. E., and Eckert, G. P. (2010). Isoprenoids, small GTPases and Alzheimer's disease. Biochim. Biophys. Acta 1801, 896-905. doi: 10.1016/j.bbalip.2010.03.014
63. Hooper, C., Killick, R., and Lovestone, S. (2008). The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104, 1433-1439. doi: 10.1111/j.1471-4159.2007.05194.x
64. Hosfield, D. J., Zhang, Y., Dougan, D. R., Broun, A., Tari, L. W., Swanson, R. V., et al. (2004). Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J. Biol. Chem. 279, 8526-8529. doi: 10.1074/jbc.C300511200
65. Huynh, T., Cordato, D., Yang, F., Choy, T., Johnstone, K., Bagnall, F., et al. (2002). HMG CoA reductase inhibitor-related myopathy and the influence of drug interactions. Intern. Med. J. 32, 486-490. doi: 10.1046/j.1445-5994.2002.00264.x
66. Ichikawa, M., Ohtsuka, M., Ohki, H., Haginoya, N., Itoh, M., Sugita, K., et al. (2012). Discovery of novel tricyclic compounds as squalene synthase inhibitors. Bioorg. Med. Chem. 20, 3072-3093. doi: 10.1016/j.bmc.2012.02.054
67. Ichikawa, M., Ohtsuka, M., Ohki, H., Ota, M., Haginoya, N., Itoh, M., et al. (2013). Discovery of DF-461, a Potent Squalene Synthase Inhibitor. ACS Med. Chem. Lett. 4, 932-936. doi: 10.1021/ml400151c
68. Ichikawa, M., Yokomizo, A., Itoh, M., Sugita, K., Usui, H., Shimizu, H., et al. (2011). Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors. Bioorg. Med. Chem. 19, 1930-1949. doi: 10.1016/j.bmc.2011.01.065
69. Iguchi, K., Tatsuda, Y., Usui, S., and Hirano, K. (2010). Pamidronate inhibits antiapoptotic bcl-2 expression though inhibition of the mevalonate pathway in prostate cancer PC-3 cells. Eur. J. Pharmacol. 641, 35-40. doi: 10.1016/j.ejphar.2010.05.010
70. Ishihara, T., Kakuta, H., Moritani, H., Ugawa, T., and Yanagisawa, I. (2004). Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Bioorg. Med. Chem. 12, 5899-5908. doi: 10.1016/j.bmc.2004.08.033
71. Iwasawa, Y., Hayashi, M., Nomoto, T., Shibata, J., Mitsuya, M., Hirota, K., et al. (1995). Synthesis and biological activity of J-104118, a novel potent inhibitor of squalene synthase. Bioorg. Med. Chem. Lett. 5, 1989-1994. doi: 10.1016/0960-894X(95)00339-U
72. Jahnke, W., and Henry, C. (2010). An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem 5, 770-776. doi: 10.1002/cmdc.201000016
73. Jahnke, W., Rondeau, J.-M., Cotesta, S., Marzinzik, A., Pellé, X., Geiser, M., et al. (2010). Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat. Chem. Biol. 6, 660-666. doi: 10.1038/nchembio.421
74. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. (2000). Statins and the risk of dementia. Lancet 356, 1627-1631. doi: 10.1016/S0140-6736(00)03155-X
75. Kampinga, H. H., and Craig, E. A. (2010). The HSP70 chaperone machinery J proteins as drivers of functional specificity. Nat. Rev. Mol. Cell Biol. 11, 579-592. doi: 10.1038/nrm2941
76. Kavanagh, K. L., Dunford, J. E., Bunkoczi, G., Russell, R. G., and Oppermann, U. (2006b). The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J. Biol. Chem. 281, 22004-22012. doi: 10.1074/jbc.M602603200
77. Kavanagh, K. L., Guo, K., Dunford, J. E., Wu, X., Knapp, S., Ebetino, F. H., et al. (2006a). The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl. Acad. Sci. U.S.A. 103, 7829-7834. doi: 10.1073/pnas.0601643103
78. Kho, Y., Kim, S. C., Jiang, C., Barma, D., Kwon, S. W., Cheng, J., et al. (2004). A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc. Natl. Acad. Sci. U.S.A. 101, 12479-12484. doi: 10.1073/pnas.0403413101
79. Kourounakis, A. P., Matralis, A. N., and Nikitakis, A. (2010). Design of more potent squalene synthase inhibitors with multiple activities. Bioorg. Med. Chem. 18, 7402-7412. doi: 10.1016/j.bmc.2010.09.008
80. Kunnas-Hiltunen, S., Matilainen, M., Vepsäläinen, J. J., and Ahlgrén, M. (2009). X-ray diffraction study of bisphosphonate metal complexes: Mg, Sr and Ba complexes of (dichloromethylene)bispho-sphonic acid P, P'-dibenzoyl anhydride. Polyhedron 28, 200-204. doi: 10.1016/j.poly.2008.10.030
81. Kunzmann, V., Bauer, E., and Wilhelm, M. (1999). γδ T-Cell Stimulation by Pamidronate. N. Engl. J Med. 340, 737-738. doi: 10.1056/NEJM199903043400914
82. Ladopoulou, E. M., Matralis, A. N., and Kourounakis, A. P. (2013). New Multifunctional di-tert-butyl-phenol-octahydro(pyrido/benz)oxazine Deri-vatives with antioxidant, antihyperlipidemic and antidiabetic action. J. Med. Chem. 56, 3330-3338. doi: 10.1021/jm400101e
83. Laufs, U., La Fata, V., Plutzky, J., James, K., and Liao, J. K. (1998). Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135. doi: 10.1161/01.CIR.97.12.1129
84. Lawrence, R. M., Biller, S. A., Dickson, J. K. Jr., Logan, J. V. H., Magnin, D. R., Sulsky, R. B., et al. (1996). Enantioselective synthesis of α-phosphono sulfonate squalene synthase inhibitors: chiral recognition in the interactions of an α-phosphono sulfonate inhibitor with squalene synthase. J. Am. Chem. Soc. 118, 11668-11669. doi: 10.1021/ja962505o
85. Lerner, E. C., Zhang, T.-T., Knowles, D. B., Qian, Y., Hamilton, A. D., and Sebti, S. M. (1997). Inhibition of the prenylation of K-Ras, but not H-or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15, 1283-1288. doi: 10.1038/sj.onc.1201296
86. Leung, C.-Y., Langille, A. M., Mancuso, J., and Tsantrizos, Y. S. (2013a). Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase-Parallel synthesis of analogs via a thrimethylsilyl ylidene intermediate. Bioorg. Med. Chem. Lett. 21, 2229-2240. doi: 10.1016/j.bmc.2013.02.006
87. Leung, C. Y., Park, J., De Schutter, J. W., Sebag, M., Berghuis, A. M., and Tsantrizos, Y. S. (2013b). Thienopyrimidine Bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition. J. Med. Chem. 56, 7939-7950. doi: 10.1021/jm400946f
88. Levy, H. B., and Kohlhaas, H. K. (2006). Considerations for supplementing with coenzyme Q10 during statin therapy. Ann. Pharmacother. 40, 290-294. doi: 10.1345/aph.1G409
89. Li, G., Larson, E. B., Sonnen, J. A., Shofer, J. B., Petrie, E. C., Schantz, A., et al. (2007). Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69, 878-885. doi: 10.1212/01.wnl.0000277657.95487.1c
90. Li, J., Herold, M. J., Kimmel, B., Müller, I., Rincon-Orozco, B., Volker Kunzmann, V., et al. (2009). Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ 2 T Cells. J. Immunol. 182, 8118-8124. doi: 10.4049/jimmunol.0900101
91. Liao, J. K. (2011). Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation 123, 1925-1928. doi: 10.1161/CIRCULATIONAHA.111.028571
92. Lin, Y.-S., Park, J., De Schutter, J. W., Huang, X. F., Berghuis, A. M., Sebag, M., et al. (2012). Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase-apoptosis and inhibition of ERK Phosphorylation in multiple myeloma cells. J. Med. Chem. 55, 3201-3215. doi: 10.1021/jm201657x
93. Lindert, S., Zhu, W., Liu, Y.-L., Pang, R., Oldfield, E., and McCammon, J. A. (2013). Farnesyl diphosphate synthase in hibitors from in silico screening. Chem. Bio. Drug Des. 81, 742-748. doi: 10.1111/cbdd.12121
94. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26. doi: 10.1016/S0169-409X(00)00129-0
95. Liu, C. I., Jeng, W. Y., Chang, W. J., Ko, T. P., and Wang, A. H. (2012). Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase. J. Biol. Chem. 287, 18750-18757. doi: 10.1074/jbc.M112.351254
96. Lounnas, V., Ritschel, T., Kelder, J., Mcguire, R., Bywater, R. P., and Foloppe, N. (2013). Current progress in structure-based rational drug design marks a new mindset in drug discovery. Comput. Struct. Biotechnol. J. 5:e201302011. doi: 10.5936/csbj.201302011
97. Magnin, D. R., Biller, S. A., Chen, Y., Dickson, J. K. Jr., Fryszman, O. M., Lawrence, R. M., et al. (1996). Alpha-phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. J. Med. Chem. 39, 657-660. doi: 10.1021/jm9507340
98. Magnin, D. R., Biller, S. A., Dickson, J. K. Jr., Logan, J. V., Lawrence, R. M., Chen, Y., et al. (1995). 1, 1-bisphosphonate squalene synthase inhibitors: interplay between the isoprenoid subunit and the diphosphate surrogate. J. Med. Chem. 38, 2596-2605. doi: 10.1021/jm00014a012
99. Mallinson, J. E., Constantin-Teodosiu, D., Sidaway, J., Westwood, F. R., and Greenhalf, P. L. (2009). Blunted Akt/FOXO signaling and activation of genes controlling atrophy and fuel use in statin myopathy. J. Physiol. 587, 219-230. doi: 10.1113/jphysiol.2008.164699
100. Mani, J., Vallo, S., Barth, K., Makarevic, J., Juengel, E., Bartsch, G., et al. (2012). Zoledronic acid influences growth migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer Prostatic Dis. 15, 250-255. doi: 10.1038/pcan.2012.9
101. Marchant, N. L., Reed, B. R., Sanossian, N., Madison, C. M., Kriger, S., Dhada, R., et al. (2013). The aging brain and cognition-contribution of vascular injury and αβ to mild cognitive dysfunction. JAMA Neurol. 70, 488-495. doi: 10.1001/2013.jamaneurol.405
102. Marma, M. S., Xia, Z., Stewart, C., Coxon, F., Dunford, J. E., Baron, R., et al. (2007). Synthesis and biological evaluation of α-Halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J. Med. Chem. 50, 5967-5975. doi: 10.1021/jm0702884
103. Martin, M. B., Arnold, W., Heath, H. T. III., Urbina, J. A., and Oldfield, E. (1999). Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem. Biophys. Res. Commun. 263, 754-758. doi: 10.1006/bbrc.1999.1404
104. Matralis, A. N., Katselou, M. G., Nikitakis, A., and Kourounakis, A. P. (2011). Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents. J. Med. Chem. 54, 5583-5591. doi: 10.1021/jm200763k
105. Matralis, A. N., and Kourounakis, A. P. (2014). Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties. Exploiting phenothiazine's strong antioxidant activity. J. Med. Chem. 57, 2568-2581. doi: 10.1021/jm401842e
106. Menys, V. C., and Durrington, P. N. (2003). Squalene synthase inhibitors. Br. J. Pharmacol. 139, 881-882. doi: 10.1038/sj.bjp.0705331
107. Miki, T., Kori, M., Fujishima, A., Mabuchi, H., Tozawa, R. I., Nakamura, M., et al. (2002a). Syntheses of fused heterocyclic compounds and their inhibitory activities for squalene synthase. Bioorg. Med. Chem. 10, 385-400. doi: 10.1016/S0968-0896(01)00289-9
108. Miki, T., Kori, M., Mabuchi, H., Banno, H., Tozawa, R. I., Nakamura, M., et al. (2002b). Novel 4, 1-benzoxazepinederivatives with potent squalene synthase inhibitory activities. Bioorg. Med. Chem. 10, 401-414. doi: 10.1016/S0968-0896(01)00290-5
109. Miki, T., Kori, M., Mabuchi, H., Tozawa, R. I., Nishimoto, T., Sugiyama, Y., et al. (2002c). Synthesis of novel 4, 1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J. Med. Chem. 45, 4571-4580. doi: 10.1021/jm020234o
110. Mitrofan, L. M., Pelkonen, J., and Mönkkönen, J. (2009). The level ofATP analogs and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone 45, 1153-1160. doi: 10.1016/j.bone.2009.08.010
111. Miyagi, Y., Matsumura, Y., and Sagami, H. (2007). Human geranylgeranyl diphosphate is an octamer in solution. J. Biochem. 142, 377-381. doi: 10.1093/jb/mvm144
112. Mönkkönen, H., Auriola, S., Lehenkari, P., Kellinsalmi, M., Hassinen, I. E., Vepsäläinen, J., et al. (2006). A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 147, 437-445. doi: 10.1038/sj.bjp.0706628
113. Morgan, G. J., Davies, F. E., Gregory, W. M., Cocks, K., Bell, S. E., Szubert, A. J., et al. (2010). First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial. Lancet 376, 1989-1999. doi: 10.1016/S0140-6736(10)62051-X
114. Morgan, G. J., Davies, F. E., Gregory, W. M., Szubert, A. J., Bell, S. E., Drayson, M. T., et al. (2012). Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 119, 5374-5383. doi: 10.1182/blood-2011-11-392522
115. Morita, C. T., Jin, C., Sarikonda, G., and Wang, H. (2007). Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ 2 T cells: discriminating friends from foe through the recognition of prenyl pyrophosphate antigens. Immunol. Rev. 215, 59-76. doi: 10.1111/j.1600-065X.2006.00479.x
116. Morris, L. W., Neuenschwander, K. W., Learn, K. S., and Scotese, A. C. (1995). Amine Bis-and Tri-Carbocyclic Alkane and Bis-Aryl Squalene Synthase Inhibitors. Rhone-Poulenc Rorer Pharmaceuticals Inc. WO 1995/00146
117. Naoe, M., Ogawa, Y., Takeshita, K., Morita, J., Shichijo, T., Fuji, K., et al. (2010). Zoledronate stimulates γδ T cells in prostate cancer patients. Oncol. Res. 18, 493-501. doi: 10.3727/096504010X12671222663638
118. Nguyen, U. T. T., Guo, Z., Delon, C., Wu, Y., Deraeve, C., Fränzel, B., et al. (2009). Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. Nat. Chem. Biol. 5, 227-235. doi: 10.1038/nchembio.149
119. Nishimoto, T., Amano, Y., Tozawa, R. I., Ishikawa, E., Imura, Y., Yukimasa, H., et al. (2003a). Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br. J. Pharmacol. 139, 911-918. doi: 10.1038/sj.bjp.0705332
120. Nishimoto, T., Tozawa, R., Amano, Y., Wada, T., Imura, Y., and Sugiyama, Y. (2003b). Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem. Pharmacol. 66, 2133-2139. doi: 10.1016/j.bcp.2003.08.011
121. Nishimoto, T., Ishikawa, E., Anayama, H., Hamajyo, H., Nagai, H., Hirakata, M., et al. (2007). Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol. Appl. Pharmacol. 223, 39-45. doi: 10.1016/j.taap.2007.05.005
122. Notarnicola, M., Messa, C., Cavallini, A., Bifulco, M., Tecce, M. F., Eletto, D., et al. (2004). Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology 67, 351-358. doi: 10.1159/000082918
123. Ohm, T. G., Treiber-Held, S., Distl, R., Glöckner, F., Schönheit, B., Tamanai, M., et al. (2003). Cholesterol and tau Protein-Findings in Alzheimer's and niemann pick c's diseases. Pharmacopsychiatry 36(Suppl. 2), S120-S126. doi: 10.1055/s-2003-43060
124. Owen, S. C., Doak, A. K., Wassam, P., Shoichet, M. S., and Schoichet, B. K. (2012). Coloidal aggregattion affects the efficacy of anticancer drugs in cell culture. ACS Chem. Biol. 7, 1429-1435. doi: 10.1021/cb300189b
125. Pandit, J., Danley, D. E., Schulte, G. K., Mazzalupo, S., Pauly, T. A., Hayward, C. M., et al. (2000). Crystal structure of human squalene synthase: a key enzyme in cholesterol biosynthesis. J. Biol. Chem. 275, 30610-30617. doi: 10.1074/jbc.M004132200
126. Park, J., Lin, Y. S., De Schutter, J. W., Tsantrizos, Y. S., and Berghuis, A. M. (2012). Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure. BMC Struct. Biol. 12:32. doi: 10.1186/1472-6807-12-32
127. Park, J., Lin, Y. S., Tsantrizos, Y. S., and Berghuis, A. M. (2014). Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate. Acta Crystallogr. F Struct. Biol. Commun. 70, 299-304. doi: 10.1107/S2053230X14002106
128. Peukert, S., Sun, Y., Zhang, R., Hurley, B., Sabio, M., Shen, X., et al. (2008). Design and structure-activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones. Bioorg. Med. Chem. Lett. 18, 1840-1844. doi: 10.1016/j.bmcl.2008.02.009
129. Poulter, C. D., Argyle, J. C., and Mash, E. A. (1978). Farnesyl pyrophosphate synthetase. Mechanistic studies of the 1'-4 coupling reaction with 2-fluorogeranyl pyrophosphate. J. Biol. Chem. 253, 7227-7233.
130. Poulter, C. D., Capson, T. L., Thompson, M. D., and Bard, R. S. (1989). Squalene synthetase inhibition by ammonium analogues of carbocationic intermediates in the conversion of presqualene diphosphate to squalene. J. Am. Chem. Soc. 111, 3734-3739. doi: 10.1021/ja00192a036
131. Prashad, M., Kathawala, F. G., and Scallen, T. (1993). N-(arylalkyl)farnesylamines: new potent squalene synthase inhibitors. J. Med. Chem. 36, 1501-1504. doi: 10.1021/jm00062a026
132. Preiss, D., Kondapally, S. R., Welsh, P., Murphy, S. A., Ho, J. E., Waters, D. D., et al. (2011). Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 305, 2556-2564. doi: 10.1001/jama.2011.860
133. Räikkönen, J., Mönkkönen, H., Auriola, S., and Mönkkönen, J. (2010). Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem. Pharmacol. 79, 777-783. doi: 10.1016/j.bcp.2009.10.003
134. Räikkönen, J., Taskinen, M., Dunford, J. E., Mönkkönen, H., Auriola, S., and Mönkkönen, J. (2011). Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonate in cultured cells. Bioche. Biophys. Res. Commun. 407, 663-667. doi: 10.1016/j.bbrc.2011.03.070
135. Reed, B. C., and Rilling, H. C. (1975). Crystallization and partial characterization of prenyltransferase from avian liver. Biochemistry 14, 50-54. doi: 10.1021/bi00672a009
136. Riekse, R. G., Li, G., Petrie, E. C., Leverenz, J. B., Vavrek, D., Vuletic, S., et al. (2006). Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J. Alzheimers Dis. 10, 399-406.
137. Rikitake, Y., and Liao, J. K. (2005). Rho GTPases, statins, and nitric oxide. Circ. Res. 97, 1232-1235. doi: 10.1161/01.RES.0000196564.18314.23
138. Ripamonti, C. I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., et al. (2009). Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 20, 137-145. doi: 10.1093/annonc/mdn526
139. Rizzoli, R., Burlet, N., Gahall, D., Delmas, P. D., Eriksen, E. F., Felsenberg, D., et al. (2008). Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42, 841-847. doi: 10.1016/j.bone.2008.01.003
140. Rondeau, J. M., Bitsch, F., Bourgier, E., Geiser, M., Hemmig, R., Kroemer, M., et al. (2006). Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 1, 267-273. doi: 10.1002/cmdc.200500059
141. Rowell, C. A., Kowalczyl, J. J., Lewis, M. D., and Garcia, A. M. (1997). Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272, 14093-14097. doi: 10.1074/jbc.272.22.14093
142. Rowinsky, E. K. (2006). Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J. Clin. Oncol. 24, 2981. doi: 10.1200/JCO.2006.05.9808
143. Russell, R. G. G. (2011). Bisphosphonates: the first 40 years. Bone 49, 2-19. doi: 10.1016/j.bone.2011.04.022
144. Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Bucklay, B. M., de Graen, A. J. M., et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375, 735-742. doi: 10.1016/S0140-6736(09)61965-6
145. Sayas, C. L., Moreno-Flores, M. T., Avila, J., and Francisco Wandosell, F. (1999). The Neurite Retraction Induced by Lysophosphatidic Acid Increases Alzheimer's Disease-like Tau Phosphorylation. J. Biol. Chem. 274, 37046-37052. doi: 10.1074/jbc.274.52.37046
146. Shiomi, M., Yamada, S., Amano, Y., Nishimoto, T., and Ito, T. (2008). Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Br. J. Pharmacol. 154, 949-957. doi: 10.1038/bjp.2008.143
147. Shmeeda, H., Amitay, Y., Gorin, J., Tsemach, D., Mak, L., Ogorka, J., et al. (2010). Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J. Control. Release 146, 76-83. doi: 10.1016/j.jconrel.2010.04.028
148. Shull, L. W., Wiemer, A. J., Hohl, R. J., and Wiemer, D. F. (2006). Synthesis and biological activity of isoprenoid bisphosphonates. Bioorg. Med. Chem. 14, 4130-4136. doi: 10.1016/j.bmc.2006.02.010
149. Silva, T., Teixeira, J., Remião, F., and Borges, F. (2013). Alzheimer's disease, cholesterol, and statins: the junction of important metabolic pathways. Angew. Chem. Int. Ed. 52, 1110-1121. doi: 10.1002/anie.201204964
150. Skerjanec, A., Berenson, J., Hsu, C., Major, P., Miller, W. H. Jr., Ravera, C., et al. (2003). The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol. 43, 154-162. doi: 10.1177/0091270002239824
151. Song, L., and Poulter, C. D. (1994). Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II. Proc. Natl. Acad. Sci. U.S.A. 91, 3044-3048. doi: 10.1073/pnas.91.8.3044
152. Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., et al. (2014). Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 16, 357-366. doi: 10.1038/ncb2936
153. Sparano, J. A., Moulder, S., Kazi, A., Coppola, D., Negassa, A., Vahdat, L., et al. (2009). Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIC breast cancer. Clin. Cancer Res. 15, 2942-2948. doi: 10.1158/1078-0432.CCR-08-2658
154. Sparks, D. L. (1997). Coronary artery disease, hypertension, apoE and cholesterol: a link to Alzheimer's diseases? Ann. N.Y. Acad. Sci. 826, 128-146. doi: 10.1111/j.1749-6632.1997.tb48466.x
155. Sparks, D. L., Hunsaker, J. C. III., Scheff, S. W., Kryscio, R. J., Henson, J. L., and Markesbery, W. R. (1990). Cortical senile plaques in coronary artery disease, aging and Alzheimer's diseases. Neurobiol. Aging 11, 601-607. doi: 10.1016/0197-4580(90)90024-T
156. Stark, J. L., Mehla, K., Chaika, N., Acton, T. B., Xiao, R., Singh, P. K., et al. (2014). Structure and function of human dnaj homologues subfamily A Member 1 (DNAJA1) and its relationship to pancreatic cancer. Biochemistry 53, 1360-1372. doi: 10.1021/bi401329a
157. Stein, E. A., Bays, H., O'Brien, D., Pedicano, J., and Piper, E., Spezzi, A. (2011). Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation 123, 1974-1985. doi: 10.1161/CIRCULATIONAHA.110.975284
158. Szabo, C. M., Matsumura, Y., Fukura, S., Martin, M. B., Sanders, J. M., Sengupta, S., et al. (2002). Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiparasitic agents. J. Med. Chem. 45, 2185-2196. doi: 10.1021/jm010412y
159. Takai, Y., Sasaki, T., and Matozaki, T. (2001). Small GTP-binding proteins. Physiol. Rev. 81, 153-208.
160. Tansey, T. R., and Shechter, I. (2001). Squalene synthase: structure and regulation. Proq. Nucleic Acid Res. Mol. Biol. 65, 157-195. doi: 10.1016/S0079-6603(00)65005-5
161. Tarshis, L. C., Proteau, P. J., Kellogg, B. A., Sacchettini, J. C., and Poulter, C. D. (1996). Regulation of product chain length by isoprenyl diphosphate synthase. Proc. Natl. Acad. Sci. U.S.A. 93, 15018-15023. doi: 10.1073/pnas.93.26.15018
162. Tavridou, A., Kaklamanis, L., Papalois, A., Kourounakis, A. P., Rekka, E. A., Kourounakis, P. N., et al. (2007). ER2306 [2-(4-Biphenyl)-4-methyl-octahydro-1, 4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. J. Pharmacol. Exp. Ther. 323, 794-804. doi: 10.1124/jpet.107.126375
163. Tavridou, A., Kaklamanis, L., Papalois, A., Kourounakis, A. P., Rekka, E. A., Kourounakis, P. N., et al. (2008). Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit. J. Cardiovasc. Pharmacol. 51, 573-580. doi: 10.1097/FJC.0b013e31817885fe
164. Thiel, K. A. (2004). Structure-aided drug design's next generation. Nat. Biotechnol. 22, 513-519. doi: 10.1038/nbt0504-513
165. Todenhöfer, T., Hennenlotter, J., Kühs, U., Gerber, V., Gakis, G., Vogel, U., et al. (2013). Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in diseases progression? World J. Urol. 31, 345-350. doi: 10.1007/s00345-012-0844-y
166. Ullrich, J. W., Kiesow, T. J., Neuenschwander, K. W., Scotese, A. C., Learn, K. S., and Dankulich, W. P. (1994). Cycloalkyl Amine Bis-Aryl Squalene Synthase Inhibitors. Rhone-Poulenc Rorer Pharmaceuticals Inc. WO 1994/14435
167. Vaidya, S., Bostedor, R., Kurtz, M. M., Bergstrom, J. D., and Bansal, V. S. (1998). Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch. Biochem. Biophys. 355, 84-92. doi: 10.1006/abbi.1998.0704
168. Verdine, G. L., and Walensky, L. D. (2007). The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264-7270. doi: 10.1158/1078-0432.CCR-07-2184
169. Wang, H., Sarikonda, G., Puan, K.-J., Tanaka, Y., Feng, J., Giner, J.-L., et al. (2011). Indirect stimulation of human Vγ2Vδ 2 T cells through alterations in isoprenoid metabolism. J. Immunol. 187, 5099-5113. doi: 10.4049/jimmunol.1002697
170. Wasko, B. M., Dudakovic, A., and Hohl, R. J. (2011). Bisphosphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J. Pharamacol. Exp. Ther. 337, 540-546. doi: 10.1124/jpet.110.175521
171. Weiss, H. M., Pfaar, U., Schweitzer, A., Wiegand, H., Skerjanec, A., and Schran, H. (2008). Biodistribution and plasma protein binding of zoledronic acid. Drug Metab. Dispos. 36, 2043-2049. doi: 10.1124/dmd.108.021071
172. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., et al. (1997). K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464. doi: 10.1074/jbc.272.22.14459
173. Wolozin, B., Wang, S. W., Li, N. C., Lee, A., Lee, T. A., and Kazis, L. E. (2007). Simvastatin is associated with a reduced incidence of dementia and Parkinson's diseases. BMC Med 5:20. doi: 10.1186/1741-7015-5-20
174. Wood, W. G., Li, L., Müller, W. E., and Eckert, G. P. (2014a). Cholesterol as a causative factor in Alzheimer's diseases: a debatable hypothesis. J. Neurochem. 129, 559-572. doi: 10.1111/jnc.12637
175. Wood, W. G., Müller, W. E., and Eckert, G. P. (2014b). Statins and neuroprotection: basic pharmacology needed. Mol. Neurobiol. doi: 10.1007/s12035-014-8647-3. [Epub ahead of print].
176. Yokoyama, K., Zimmerman, K., Scholten, J., and Gelb, M. H. (1997). Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-i and protein farnesyltransferase and its consequence on the specificity of protein prenylation. J. Biol. Chem. 272, 3944-3952. doi: 10.1074/jbc.272.7.3944
177. Young, S. G., Fong, L. G., and Michaelis, S. (2005). Prelamin, A., Zmpste24, misshapen cell nuclei, and progeria-new evidence suggesting that protein farnesylation could be important for diseases pathogenesis. J. Lipid Res. 46, 2531-2558. doi: 10.1194/jlr.R500011-JLR200
178. Yu, D.-C., Liu, J., Chen, J., Shao, J.-J., Shen, X., Xia, H.-G., et al. (2014). GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis. BMC Cancer 14:248. doi: 10.1186/1471-2407-14-248
179. Zhang, Y., Cao, R., Yin, F., Hudock, M. P., Guo, R.-T., Krysiak, K., et al. (2009). Lipophilic bisphosphonates as dual Farnesyl/Geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J. Am. Chem. Soc. 131, 5153-5162. doi: 10.1021/ja808285e
180. Zhang, Y., Cao, R., Yin, F., Lin, F.-Y., Wang, H., Krysiak, K., et al. (2010). Lipophilic pyridinium bisphosphonates: potent γδ T cell stimulators. Angew. Chem. Int. Ed. 49, 1136-1138. doi: 10.1002/anie.200905933
181. Zhang, Y., Leon, A., Song, Y., Studer, D., Haase, C., Koscielski, L. A., et al. (2006). Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines. J. Med. Chem. 49, 5804-5814. doi: 10.1021/jm060280e